Internship

Antibody Developability Intern – 8-month Co-op/Internship

Posted on 11/15/2024

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Biotechnology
Healthcare

Compensation Overview

CA$19.04 - CA$21.35Hourly

Vancouver, BC, Canada

Workplace arrangement is on-site.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Currently pursuing a BSc degree in the life sciences
  • Previous hands-on wet lab experience
  • Keen desire to learn new skills in an industry setting
  • Previous co-op experience would be considered an asset
  • Enrolled in a BSc program in Biophysics, Biochemistry, Biology, Biotechnology, Structural Biology, or a related life sciences field
  • Strong interpersonal skills
  • Eager to learn and develop new technical skills
Responsibilities
  • Learning and conducting high throughput characterization of antibodies, bi- and multi-specifics using a variety of analytical and biophysical techniques
  • Supporting the assessment of developability properties of hundreds of antibodies through characterization assays, such as non-specific binding ELISA, self-interaction assays, analytical size exclusion chromatography (aSEC), and hydrophobic interaction chromatography (aHIC)
  • Collaborating with teammates to troubleshoot, analyze, interpret, and communicate data effectively
  • Growing your technical expertise by gaining hands-on experience with advanced methodologies, and contributing to cutting-edge scientific research in a dynamic and collaborative environment
  • Participating in team meetings to share updates and insights on ongoing experiments and projects
  • Assisting in refining experimental protocols and performing data analysis using relevant software and tools

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Grant

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

5%

1 year growth

0%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.

Help us improve and share your feedback! Did you find this helpful?